

## P&T Motion History Overactive Bladder

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<u>Antimuscarinic agents</u> darifenacin fesoterodine fumarate flavoxate HCL oxybutynin chloride solifenacin tolterodine tartrate trospium chloride  <u>Beta-3 adrenergic agonists</u> mirabegron <b>vibegron</b>	After considering the evidence of safety, efficacy and special populations for the treatment of overactive bladder, I move that darifenacin, fesoterodine fumarate, flavoxate HCL, mirabegron, oxybutynin chloride, solifenacin, tolterodine tartrate, trospium chloride, and vibegron are safe and efficacious. These drugs, with the exception of trospium and darifenacin due to their neuro-selectivity, can be subject to therapeutic interchange within the same drug class in the Washington preferred drug list. Additionally immediate release formulations cannot be interchanged for a once daily formulations and vice versa. A once daily formulation must be included as a preferred drug on the Washington preferred drug list.  Motion: Beste 2 <sup>nd</sup> : Barkett	June 26, 2024	N/A	No	Passed unanimous